title: [Usefulness of caerulein in suppressing post-TAE complications of the gallbladder].
abstract: While transcatheter hepatic arterial embolization (TAE) has been extensively performed as a form of treatment for nonresectable malignant hepatic tumors, complications, such as abdominal pain, fever or leukocytosis due to gallbladder infarction by embolic materials frequently occur and have not yet been overcome. We devised a new procedure for reducing the incidence of gallbladder infarction by administering caerulein prior to TAE. Between 1984 and 1986, 63 patients with hepatocellular carcinoma were treated by TAE with the use of Gelfoam. These patients were divided into 3 groups. Fourteen patients underwent TAE in which the tip of the catheter was placed in the right hepatic artery distal to the origin of the cystic artery (group A). In the other patients the tip of the catheter was placed proximal to the origin of the cystic artery; 40 patients were not treated by caerulein (group B); 9 patients were administered caerulein 20 micrograms intramuscularly 15 to 30 minutes prior to TAE. The incidence of complications after TAE, such as abdominal pain, fever over 38 degrees C, leukocytosis and ultrasonographical abnormalities of the gallbladder was compared in these 3 groups. The results showed that in group C (TAE after administration of caerulein), the incidence of complications was significantly decreased compared with group B(TAE without caerulein). The authors suggest that post-TAE infarction of the gallbladder is effectively diminished by contracting it with caerulein.
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D002108:Ceruletide / Q000627:therapeutic use*; D004621:Embolization, Therapeutic / Q000009:adverse effects* / Q000379:methods; D005704:Gallbladder / Q000098:blood supply*; D006801:Humans; D007238:Infarction / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000628:therapy*
chemical_list: D002108:Ceruletide